SMA Capital’s Bristol-Myers Squibb BMY Stock Holding History

SMA Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-359	Closed	-$21.8K	–	128
2026 Q1	$21.8K	Buy	+359	New	+$20.9K	0.01%	48

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SMA Capital's BMY Position: Q2 2026 in Review

SMA Capital sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 359 shares — an estimated $21.8K sold.

SMA Capital first reported a position in BMY in Q1 2026 and held it in 1 quarter. The position peaked at $21.8K in Q1 2026. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

SMA Capital reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
SMA Capital sold 359 Bristol-Myers Squibb shares in Q2 2026, an estimated $21.8K.
SMA Capital first reported a position in Bristol-Myers Squibb in Q1 2026 and held it in 1 quarter.
SMA Capital's Bristol-Myers Squibb position peaked at $21.8K in Q1 2026.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.